10月10日，迈威生物盘中下跌2.05%，截至10:57，报46.41元/股，成交2.13亿元，换手率2.22%，总市值 185.45亿元。 资金流向方面，主力资金净流出3052.38万元，特大单买入1024.10万元，占比4.80%，卖出2514.43万 元，占比11.80%；大单买入5522.22万元，占比25.91%，卖出7084.27万元，占比33.23%。 迈威生物今年以来股价涨129.75%，近5个交易日跌9.36%，近20日跌14.40%，近60日涨46.27%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、眼科概念、抗 癌治癌、抗癌药物、创新药等。 截至6月30日，迈威 ...

分红方面，吉贝尔A股上市后累计派现4.76亿元。近三年，累计派现2.96亿元。 责任编辑：小浪快报 吉贝尔所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：创新药、抗癌药物、生物 医药、抗癌治癌、高血压防治等。 截至6月30日，吉贝尔股东户数6003.00，较上期减少17.68%；人均流通股33221股，较上期增加 21.47%。2025年1月-6月，吉贝尔实现营业收入4.55亿元，同比增长4.90%；归母净利润1.49亿元，同比 增长22.38%。 资金流向方面，主力资金净流出372.05万元，特大单买入0.00元，占比0.00%，卖出140.04万元，占比 3.74%；大单买入738.20万元，占比19.73%，卖出970.21万元，占比25.93%。 吉贝尔今年以来股价涨59.41%，近5个交易日跌2.43%，近20日跌10.01%，近60日涨17.60%。 资料显示，江苏吉贝尔药业股份有限公司位于江苏省镇江市高新技术产业开发园区，成立日期2001年11 月13日，上市日期2020年5月18日，公司主营业务涉及专业从事药品研发、生产、销售。主营业务收入 构成为：利可君片72.72%，尼群洛 ...

10月9日，益方生物盘中下跌2.03%，截至13:04，报30.48元/股，成交1.85亿元，换手率1.42%，总市值 176.28亿元。 截至6月30日，益方生物股东户数9790.00，较上期减少7.28%；人均流通股40990股，较上期增加 7.85%。2025年1月-6月，益方生物实现营业收入1916.38万元，同比增长28.85%；归母净利润-1.19亿 元，同比增长44.25%。 益方生物今年以来股价涨129.17%，近5个交易日跌9.61%，近20日跌29.22%，近60日跌4.00%。 机构持仓方面，截止2025年6月30日，益方生物十大流通股东中，汇添富创新医药混合A（006113）位 居第四大流通股东，持股996.19万股，为新进股东。中欧医疗健康混合A（003095）位居第五大流通股 东，持股909.24万股，相比上期增加79.05万股。香港中央结算有限公司位居第六大流通股东，持股 805.41万股，为新进股东。睿远成长价值混合A（007119）位居第七大流通股东，持股787.01万股，相 比上期增加56.85万股。鹏华医药科技股票A（001230）退出十大流通股东之列。 今年以来益方生物 ...

Group 1 - The core viewpoint of the news is that Yingkang Life has shown a positive stock performance with a year-to-date increase of 24.46% and a recent price of 11.45 CNY per share, despite some fluctuations in trading volume and net capital outflow [1] - As of September 19, the number of shareholders for Yingkang Life decreased by 16.28% to 20,500, while the average circulating shares per person increased by 19.45% to 31,286 shares [2] - The company reported a revenue of 843 million CNY for the first half of 2025, reflecting a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million CNY, which is a 12.82% increase year-on-year [2] Group 2 - Yingkang Life specializes in medical devices and services, focusing on cancer prevention, diagnosis, treatment, and rehabilitation, with a revenue composition of 77.47% from medical services and 22.53% from medical devices and consumables [2] - The company has cumulatively distributed 29.48 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]

Core Viewpoint - Yifang Bio has shown significant stock price fluctuations and performance metrics, indicating both growth potential and recent challenges in the market [1][2]. Group 1: Stock Performance - As of September 30, Yifang Bio's stock price increased by 2.00% to 31.55 CNY per share, with a trading volume of 1.27 billion CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 18.247 billion CNY [1]. - Year-to-date, Yifang Bio's stock price has risen by 137.22%, but it has experienced a decline of 3.58% over the last five trading days and 22.80% over the last 20 days [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 11, where it recorded a net purchase of 68.8706 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yifang Bio reported a revenue of 19.1638 million CNY, reflecting a year-on-year growth of 28.85%, while the net profit attributable to shareholders was -119 million CNY, an increase of 44.25% compared to the previous period [2]. - As of June 30, 2025, the number of shareholders decreased by 7.28% to 9,790, while the average circulating shares per person increased by 7.85% to 40,990 shares [2]. Group 3: Shareholder Composition - As of June 30, 2025, notable institutional shareholders include Huatai-PineBridge Innovation Medicine Mixed A, which is the fourth largest shareholder with 9.9619 million shares, and Central Clearing Hong Kong Limited, which is a new shareholder with 8.0541 million shares [2]. - The fifth largest shareholder, China Europe Medical Health Mixed A, increased its holdings by 790,500 shares to 9.0924 million shares [2].

Core Viewpoint - As of September 30, 2023, Aosaikang's stock price increased by 2.03% to 20.57 CNY per share, with a market capitalization of 19.092 billion CNY, despite a net outflow of main funds amounting to 14.2823 million CNY [1] Group 1: Stock Performance - Aosaikang's stock has risen by 63.38% year-to-date, but has seen a decline of 1.20% over the last five trading days and 11.83% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 16 [1] Group 2: Financial Performance - For the first half of 2025, Aosaikang reported a revenue of 1.007 billion CNY, representing a year-on-year growth of 9.20%, and a net profit attributable to shareholders of 160 million CNY, which is a significant increase of 111.64% [2] - Cumulatively, Aosaikang has distributed 721 million CNY in dividends since its A-share listing, with 111 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of September 20, 2023, Aosaikang had 20,000 shareholders, an increase of 2.46% from the previous period, with an average of 46,298 circulating shares per shareholder, down by 2.40% [2] - Notable changes in institutional holdings include the entry of Yongying Medical Innovation Mixed Fund as the sixth largest shareholder, holding 11.6856 million shares, and the exit of several funds from the top ten shareholders list [3]

资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10月 28日，上市日期2021年12月15日，公司主营业务涉及研究、开发、生产以及商业化创新型药物。主营业 务收入构成为：药品销售收入99.10%，合作安排收入0.90%。 百济神州所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、H股、百元 股、基金重仓、抗癌药物等。 9月30日，百济神州盘中上涨2.02%，截至10:49，报307.09元/股，成交5.59亿元，换手率1.59%，总市值 4731.27亿元。 资金流向方面，主力资金净流出1907.92万元，特大单买入5861.36万元，占比10.48%，卖出4989.87万 元，占比8.93%；大单买入1.41亿元，占比25.15%，卖出1.68亿元，占比30.12%。 百济神州今年以来股价涨90.72%，近5个交易日涨1.17%，近20日跌5.47%，近60日涨37.62%。 今年以来百济神州已经1次登上龙虎榜，最近一次登上龙虎榜为9月2日。 截至6月30日，百济神州股东户数2.33万，较上期减少3.90%；人均流通股4976股，较上期增 ...

舒泰神所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、创新药、仿制 药、抗癌治癌、年度强势等。 截至6月30日，舒泰神股东户数3.17万，较上期增加29.20%；人均流通股14327股，较上期减少22.60%。 2025年1月-6月，舒泰神实现营业收入1.26亿元，同比减少31.14%；归母净利润-2463.56万元，同比减少 619.70%。 9月30日，舒泰神盘中上涨2.29%，截至10:10，报34.42元/股，成交1.55亿元，换手率1.00%，总市值 164.45亿元。 资金流向方面，主力资金净流出113.12万元，特大单买入136.00万元，占比0.88%，卖出0.00元，占比 0.00%；大单买入2157.65万元，占比13.95%，卖出2406.77万元，占比15.57%。 舒泰神今年以来股价涨364.51%，近5个交易日跌1.15%，近20日跌29.02%，近60日跌15.28%。 今年以来舒泰神已经7次登上龙虎榜，最近一次登上龙虎榜为6月9日，当日龙虎榜净买入-5465.02万 元；买入总计1.08亿元 ，占总成交额比4.87%；卖出总计1.63亿元 ，占总成交额 ...

Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with a significant revenue contribution from injectable nerve growth factor (Sutai) at 59.17% and compound polyethylene glycol electrolyte powder at 33.19% [1][2] Stock Performance - As of September 29, Shuyou Shen's stock price decreased by 2.10% to 33.16 CNY per share, with a total market capitalization of 15.843 billion CNY [1] - The stock has seen a year-to-date increase of 347.50%, but has declined by 8.68% over the last five trading days, 38.43% over the last 20 days, and 24.84% over the last 60 days [1] Financial Performance - For the first half of 2025, Shuyou Shen reported a revenue of 126 million CNY, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.636 million CNY, a decline of 619.70% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares per shareholder, down by 22.60% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Institutional Holdings - Notable new institutional shareholders include Xingquan He Run Mixed A, holding 15.721 million shares, and several other funds, indicating a shift in shareholder composition [3]

9月25日，泰恩康盘中下跌2.07%，截至10:18，报33.66元/股，成交6341.35万元，换手率0.62%，总市值 143.22亿元。 泰恩康所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：合成生物、创新药、眼科 概念、抗癌药物、抗癌治癌等。 截至6月30日，泰恩康股东户数1.09万，较上期减少33.05%；人均流通股27747股，较上期增加49.36%。 2025年1月-6月，泰恩康实现营业收入3.47亿元，同比减少12.23%；归母净利润3708.48万元，同比减少 56.75%。 泰恩康今年以来股价涨127.57%，近5个交易日跌7.09%，近20日跌4.62%，近60日跌9.39%。 资料显示，广东泰恩康医药股份有限公司位于广东省汕头市龙湖区泰山北路万吉南二街8号A幢，成立 日期1999年1月22日，上市日期2022年3月29日，公司主营业务涉及代理运营及研发、生产、销售医药产 品、医疗器械、卫生材料并提供医药技术服务与技术转让等。主营业务收入构成为：医药代理 65.16%，医药制造31.70%，医药技术服务及技术转让2.97%，其他(补充)0.17%。 分红方面，泰恩康A股上 ...